Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-10-09
2007-10-09
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S145100, C424S152100, C424S158100, C424S172100, C424S810000, C514S825000, C514S885000, C530S388250, C530S389300, C530S868000, C435S004000, C435S007100, C435S007200, C435S007240, C435S029000, C436S821000
Reexamination Certificate
active
11029017
ABSTRACT:
The use of compounds that block complement component C5 or its active fragments C5aand/or C5b(such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.
REFERENCES:
patent: 5135916 (1992-08-01), Sims et al.
patent: 5173499 (1992-12-01), Sindelar et al.
patent: 5635178 (1997-06-01), Sims et al.
patent: 5853722 (1998-12-01), Rollins et al.
patent: 6074642 (2000-06-01), Wang et al.
patent: 0245993 (1987-11-01), None
patent: WO-94/03603 (1994-02-01), None
patent: WO-94/26786 (1994-11-01), None
patent: WO-95/23856 (1995-09-01), None
patent: WO-95/25540 (1995-09-01), None
patent: WO-95/29697 (1995-11-01), None
Güssow, D et al. Meth. Enzymology [1991] 203:99-117.
Abbnik et al “Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.” Annu. Rheumat. Dis, 51:1123-1128. (1992).
Anderson, R. et al. “Immunological assessment of patients with rheumatoid arthritis—evaluation of the effects of propranolol.” S.A. Medical Journal, 666-669. (1981).
Anderson et al. Letter to the editor. Immunogenetics, 35:71-72.
Anderson and Holmdahl. “Analysis of type II collagen-reactive T cells in the mouse—I. Different regulation of autoreactive vs. non-autoreactive anti-type II collagen T cells in the DBA/1 mouse.” Eur. J. Immunol., 20:1061-1066. (1990).
Andersson et al. Letter to the Editor. Immunogenet, 35:71-72. (1992).
Andersson et al. “T-cell receptor Vβ haplotype and complement component C5 play no significant role for the resistance to collagen-induced arthritis in the SWR mouse.” Immunol., 73:191-196. (1991).
Auda et al. “Measurement of complement activation products in patients with chronic rheumatic diseases.” Rheumat. Int., 10:185-189. (1990).
Banapour et al. “The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum” Virology 152:268-271. (1986).
Banerjee et al. “Influence of complement C5 and Vβ T cell receptor mutations on susceptibility to collagen-induced arthritis in mice.” J. Immunol, 142:2237-2243. (1989).
Banerjee et al. “Possible role of Vβ T cell receptor genes in susceptibility to collagen-induced arthritis in mice.” J. Exp. Med., 167:832-839. (1988).
Barbacid et al. “Humans have antibodies capable of recognizing oncoviral gllycoproteins: Demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure virus.” Proc. Natl. Acad. Sci. USA 77:1617-1621. (1980).
Bartholomew et al. “Lysis of oncornaviruses by human serum.” J. Exp. Med, 147:844-853. (1978).
Bartholomew et al. “Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes.” Biochem. 19:2847-2853. (1980).
Brahn and Trentham. “Experimental synovitis induced by collagen-specific T cell lines.” Cell Immunol., 118:491-503. (1989).
Brenner, M. “Genetic marketing and manipulation of hematopoietic progenitor cells using retroviral vectors.” Immunmethods 5:204-210. (1994).
Brodeur et al. “Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.” Arthr Rheumat, 34:1531-1537. (1990).
Chiocchia et al. “T cell regulation of collagen-induced arthritis in mice.” J. Immunol., 145:519-525. (1990).
Chiocchia et al. “Therapy against murine collagen-induced arthritis with T cell receptor Vβ-specific antibodies.” Eur J. Immunol., 21:2899-2905. (1991).
Cooper et al. “Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway.” J. Exp Med, 144:970-984. (1976).
Corvetta et al. “Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma.” Clin. Exp. Rheumat., 10:433-438. (1992).
David, “Role for T-cell receptor Vβ genes in collagen induced-arthritis.” Immunogenet, 35:69-70. (1992).
De Clerk et al. “Humoral immunity and composition of immune complexes in patients with rheumatoid arthritis, with special reference to IgE-containing immune complexes.” Clin Exp. Rheumat., 7:485-492. (1989).
Durie et al. “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.” Science, 261:1328-1330. (1993).
Fava et al. “Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis.” Clin. Exp. Immunol., 94:261-266. (1993).
Feldmann et al. “Cytokine assays: Role in evaluation of the pathogenesis of autoimmunity.” Immunol. Rev., 119:105-123. (1991).
Feldmann et al. “Cytokine production in the rheumatoid joint: Implications for treatment.” Anna Rheumat. Dis., 49:480-486. (1990).
Firestein et al. “Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium.” Arthr Rheumat., 34:1094-1105. (1991).
Fong et al. “Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: Correlation with bony erosions.” Clin. Exp. Rheumat., 12:55-58. (1994).
Frei et al. “Generation of a monoclonal antibody to mouse C5 application in an ELISA asay for detection of anti-C5 antibodies.” Mol. Cell Probes, 1:141-149. (1987).
Galili et al. “Evolution and pathophsiology of the human natural anti-a-galactosyl IgG (Anti-GaI) antibody.” Springer Semin Immunopathol, 15:155-171. (1993).
Geyer et al. “Major oligosaccharides in the glycoprotein of friend murine leukemia virus: structure elucidation by one—and two dimensional proton nuclear magnetic resonance and methylation analysis.” Biochemistry 23:5628-5637. (1984).
Goldschmidt and Holmdahl, “Anti-T cell receptor antibody treatment of rats with established autologous collagen-induced arthritis: Suppression of arthritis without reduction of anti-type II collagen autoantibody levels.” Eur. J. Immunol. 21:1327-1330. (1991).
Goldschmidt et al. “Invivo elimination of T cells expressing specific T-cell receptor Vβ chains in mice susceptible to collagen-induced arthritis.” Immunol., 69:508-514. (1990).
Hamadeh et al. “Human Natural anti-gal IgG regulates alternative complement pathway activation on bacterial surfaces.” J. Clin. Invest., 89:1223-1235. (1992).
Haqqi et al. “Identification of T-cell receptor Vβ deletion mutant mouse strain AU/ssJ (H-2q) which is resistant to collagen-induced arthritis.” Immunogenet, 29:180-185. (1989).
Harigai et al. “Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synvium.” Clin. Immunol. Immunopath, 69:83-91. (1993).
Heinz et al. “Common epitopes in Clq and collagen type II.” Mol. Immunol., 26:163-169. (1989).
Holmdahl et al. “Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum.” Scand. J. Immunol., 31:147-157. (1990).
Holmdahl et al. “Collagen induced arthritis: an experimental model for rheumatoid arthritis with involvement of both DTH and immune complex mediated mechanisms.” Clin. Exp. Rheumat., 7/S-3:57-55. (1989).
Holmdahl et al. “T lymphocytes in collagen II-induced arthritis in mice.” Scand. J. Immunol, 22:295-306. (1985).
Hom et al., “Effects of various anti-T cell receptor antibodies on the development of type II collagen-induc
Matis Louis
Wang Yi
Alexion Pharmaceuticals, Inc.
Chan Christina
Ropes & Gray LLP
VanderVegt F. Pierre
LandOfFree
Methods for the treatment of inflammatory joint disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of inflammatory joint disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of inflammatory joint disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3869238